Healthcare tech company Omnicell (NASDAQ:OMCL) reported Q3 CY2025 results beating Wall Street’s revenue expectations , with sales up 10% year on year to $310.6 million. On top of that, next quarter’s ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Omnicell (OMCL) reports results for the quarter ended June 2025. While this widely-known consensus outlook is important ...

Reports Q3 revenue $282.42M, consensus $280.45M. Randall Lipps, chairman, president, CEO, said, “We are pleased to deliver another consecutive quarter of solid financial performance, with results ...

In Q3, Omnicell reported adjusted EPS of $0.51, down from $0.56 in the same quarter last year. Despite falling year on year, this print easily cleared analysts’ estimates. Over the next 12 months, ...

Baxter approached Omnicell with a buyout offer of more than $120 a share, a report says. Baxter approached Omnicell with an offer to acquire the company for more than $5 billion, sources told Reuters.

Healthcare tech company Omnicell (NASDAQ:OMCL) will be announcing earnings results this Thursday morning. Here’s what you need to know. Omnicell beat analysts’ revenue expectations by 4.9% last ...

The market expects Omnicell (OMCL) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2020. This widely-known consensus outlook is ...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell, Inc., (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced ...